These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 11805241)

  • 21. Combination therapy in multiple sclerosis.
    Tullman MJ; Lublin FD
    Curr Neurol Neurosci Rep; 2005 May; 5(3):245-8. PubMed ID: 15865891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Newer long-term treatments for multiple sclerosis.
    Pryse-Phillips W
    Clin Neurol Neurosurg; 2002 Jul; 104(3):265-71. PubMed ID: 12127666
    [No Abstract]   [Full Text] [Related]  

  • 23. Therapy of multiple sclerosis in children and adolescents.
    Tenembaum SN
    Clin Neurol Neurosurg; 2010 Sep; 112(7):633-40. PubMed ID: 20471159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness.
    Clegg A; Bryant J
    Expert Opin Pharmacother; 2001 Apr; 2(4):623-39. PubMed ID: 11336612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disease modifying treatment in multiple sclerosis.
    Fuller GN; Bone I
    J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780
    [No Abstract]   [Full Text] [Related]  

  • 27. [Diagnosis and therapy in multiple sclerosis].
    Sailer M
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2010 May; 45(5):328-34. PubMed ID: 20455189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Confusion over UK beta-interferon "trials".
    Dean M
    Lancet; 2001 Nov; 358(9293):1619. PubMed ID: 11716901
    [No Abstract]   [Full Text] [Related]  

  • 29. [New therapeutic strategies in multiple sclerosis].
    Berger E; Rumbach L
    Rev Med Interne; 1999 Aug; 20 Suppl 3():346s-350s. PubMed ID: 10480185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recent therapeutic strategy for multiple sclerosis].
    Itoyama Y
    Rinsho Shinkeigaku; 2001 Dec; 41(12):1214-7. PubMed ID: 12235841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-specific immunosuppressants in the treatment of multiple sclerosis.
    Confavreux C; Vukusic S
    Clin Neurol Neurosurg; 2004 Jun; 106(3):263-9. PubMed ID: 15177781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative studies of glatiramer acetate and interferon beta.
    Goodin D
    Int MS J; 2008 Jun; 15(2):39-41. PubMed ID: 18782497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.
    Fox RJ; Bethoux F; Goldman MD; Cohen JA
    Cleve Clin J Med; 2006 Jan; 73(1):91-102. PubMed ID: 16444920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
    Pittock SJ; Rodriguez M
    Curr Top Microbiol Immunol; 2008; 318():1-17. PubMed ID: 18219812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Pachner AR
    Neurology; 2007 Oct; 69(15):1555; author reply 1565. PubMed ID: 17923620
    [No Abstract]   [Full Text] [Related]  

  • 36. Guidance on new therapies in multiple sclerosis patients.
    Gonsette RE
    Lancet; 1996 Jul; 348(9020):136. PubMed ID: 8676708
    [No Abstract]   [Full Text] [Related]  

  • 37. Interferon beta and glatiramer acetate therapy.
    McGraw CA; Lublin FD
    Neurotherapeutics; 2013 Jan; 10(1):2-18. PubMed ID: 23264098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of multiple sclerosis in children and adolescents.
    Kuntz NL; Chabas D; Weinstock-Guttman B; Chitnis T; Yeh EA; Krupp L; Ness J; Rodriguez M; Waubant E;
    Expert Opin Pharmacother; 2010 Mar; 11(4):505-20. PubMed ID: 20163265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects.
    Pender MP; Wolfe NP
    Intern Med J; 2002 Nov; 32(11):554-63. PubMed ID: 12412939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs.
    Tsareva E; Kulakova O; Boyko A; Favorova O
    Pharmacogenet Genomics; 2016 Mar; 26(3):103-15. PubMed ID: 26678572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.